BR112022020521A2 - Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos - Google Patents

Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos

Info

Publication number
BR112022020521A2
BR112022020521A2 BR112022020521A BR112022020521A BR112022020521A2 BR 112022020521 A2 BR112022020521 A2 BR 112022020521A2 BR 112022020521 A BR112022020521 A BR 112022020521A BR 112022020521 A BR112022020521 A BR 112022020521A BR 112022020521 A2 BR112022020521 A2 BR 112022020521A2
Authority
BR
Brazil
Prior art keywords
conjugates
phthalocianine
methods
color compounds
disclosed
Prior art date
Application number
BR112022020521A
Other languages
English (en)
Portuguese (pt)
Inventor
Betancort Juan
Makings Lew
Wiemann Torsten
J Hoey Robert
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of BR112022020521A2 publication Critical patent/BR112022020521A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/30—Metal-free phthalocyanines
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/08—Preparation from other phthalocyanine compounds, e.g. cobaltphthalocyanineamine complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/32—Cationic phthalocyanine dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy
    • Y02E10/542—Dye sensitized solar cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112022020521A 2020-04-10 2021-04-09 Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos BR112022020521A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008476P 2020-04-10 2020-04-10
US202063008502P 2020-04-10 2020-04-10
PCT/US2021/026705 WO2021207691A1 (en) 2020-04-10 2021-04-09 Phthalocyanine dye compounds, conjugates and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022020521A2 true BR112022020521A2 (pt) 2023-03-07

Family

ID=78022788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020521A BR112022020521A2 (pt) 2020-04-10 2021-04-09 Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos

Country Status (10)

Country Link
US (2) US11466158B2 (enExample)
EP (1) EP4132583A4 (enExample)
JP (3) JP7125828B2 (enExample)
KR (1) KR20230009890A (enExample)
CN (1) CN115942958A (enExample)
AU (1) AU2021251873A1 (enExample)
BR (1) BR112022020521A2 (enExample)
CA (1) CA3179937A1 (enExample)
MX (1) MX2022012721A (enExample)
WO (1) WO2021207691A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003679A (zh) * 2020-02-05 2022-09-02 国立大学法人东京大学 酞菁染料与抗体或肽的缀合物
BR112022020521A2 (pt) 2020-04-10 2023-03-07 Rakuten Medical Inc Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos
WO2022182483A1 (en) 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
EP4319817A4 (en) * 2021-04-09 2026-05-27 Rakuten Medical Inc PHTHALOCYANINE-BASED COLOUR COMPOUNDS, CONJUGATES AND ASSOCIATED PROCESSES OF USE
US12115223B2 (en) 2021-04-22 2024-10-15 The University Of Tokyo Conjugate of biotin-modified dimer and phthalocyanine dye
CN113943305B (zh) * 2021-11-15 2022-12-30 中国科学技术大学 酞菁荧光分子化合物、制备方法、酞菁荧光纳米材料
CA3252736A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-PD-L1 (Programmed Death-Ligand 1) Antibody Molecules, Coding Polynucleotides, and Methods of Use
US20260176317A1 (en) 2022-11-11 2026-06-25 Rakuten Medical, Inc. Engineered interleukin-15 polypeptides, complexes and uses thereof
EP4435060A1 (en) 2023-03-23 2024-09-25 Albert-Ludwigs-Universität Freiburg Silicon phthalocyanine and tribenzophthalocyanine dyes and their use in diagnosis and therapy
WO2025035196A1 (pt) * 2023-08-11 2025-02-20 Use Phitta Cream Ltda - Epp Creme hidratante com proteção antisséptica de ação prolongada para as mãos

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6060598A (en) * 1990-05-15 2000-05-09 Hyperion, Inc. Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding
CA2082934C (en) * 1990-05-15 2003-08-05 Walter B. Dandliker Phthalocyanatopolyethylene glycol, and phthalocyanato saccharides as fluorescent digoxin reagents
ATE206395T1 (de) 1990-05-15 2001-10-15 Hyperion Inc Fluoreszierende porphyrin- und fluoreszierende phthalocyanin-polyethylenglykol-, polyol- und saccharidderivate als fluoreszierende sonden
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5763602A (en) * 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7005518B2 (en) 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
CN1315850C (zh) 2004-06-11 2007-05-16 福州大学 轴向取代酞菁配合物、它的制备及其在光动力治疗中的应用
CN103539799B (zh) 2013-08-29 2016-01-06 中国医学科学院生物医学工程研究所 一种水溶性氨基多羧酸修饰酞菁化合物的制备方法和用途
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
ES2999358T3 (en) * 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
CA3026651A1 (en) 2016-06-09 2017-12-14 Blinkbio, Inc. Silanol based therapeutic payloads
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
CN109863346A (zh) 2016-10-25 2019-06-07 乐天医药生技股份有限公司 用于光免疫治疗的光漫射装置
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019008386A1 (en) 2017-07-06 2019-01-10 Tusk Therapeutics Ltd COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
JP2020017910A (ja) 2018-07-27 2020-01-30 ソニーセミコンダクタソリューションズ株式会社 ストリーキング補正回路、撮像装置、及び、電子機器
JP7625188B2 (ja) * 2019-09-30 2025-02-03 国立大学法人 東京大学 ビオチン改変二量体とフタロシアニン染料とのコンジュゲート
CN115003679A (zh) 2020-02-05 2022-09-02 国立大学法人东京大学 酞菁染料与抗体或肽的缀合物
BR112022020521A2 (pt) 2020-04-10 2023-03-07 Rakuten Medical Inc Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos
EP4319817A4 (en) 2021-04-09 2026-05-27 Rakuten Medical Inc PHTHALOCYANINE-BASED COLOUR COMPOUNDS, CONJUGATES AND ASSOCIATED PROCESSES OF USE

Also Published As

Publication number Publication date
CA3179937A1 (en) 2021-10-14
US20220010140A1 (en) 2022-01-13
WO2021207691A1 (en) 2021-10-14
AU2021251873A1 (en) 2022-11-10
US11466158B2 (en) 2022-10-11
EP4132583A4 (en) 2024-11-13
EP4132583A1 (en) 2023-02-15
JP7900220B2 (ja) 2026-08-04
CN115942958A (zh) 2023-04-07
JP2022191210A (ja) 2022-12-27
MX2022012721A (es) 2023-01-16
JP2022191209A (ja) 2022-12-27
JP7125828B2 (ja) 2022-08-25
KR20230009890A (ko) 2023-01-17
US12448518B2 (en) 2025-10-21
US20230399515A1 (en) 2023-12-14
JP2022527672A (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2022012721A (es) Compuestos de colorantes basados en ftalocianina, conjugados y metodos de uso de los mismos.
Horbert et al. Photoactivatable prodrugs of antimelanoma agent vemurafenib
Velema et al. Photopharmacology: beyond proof of principle
Uzdensky et al. Photodynamic effect of novel chlorin e6 derivatives on a single nerve cell
Hanlon et al. Induction of Hsp60 by Photofrin-mediated photodynamic therapy
Vecchio et al. Structure–function relationships of Nile blue (EtNBS) derivatives as antimicrobial photosensitizers
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
Osman et al. Acridine orange as a novel photosensitizer for photodynamic therapy in glioblastoma
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
Digby et al. Photocaged DNA-binding photosensitizer enables photocontrol of nuclear entry for dual-targeted photodynamic therapy
Magalhaes et al. Aminosquaraines as potential photodynamic agents: Synthesis and evaluation of in vitro cytotoxicity
CO2025001970A2 (es) Composiciones dirigidas a la proteína de activación de fibroblastos y métodos para el uso de las mismas
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
Arumugam et al. New insights into the dimerization and site-specific cooperative interaction of Azure B with model transport proteins by spectroscopic and computational studies
MX2022001515A (es) Composiciones de conjugado de cetuximab-ir700.
Bhattacharyya et al. Differential modes of photosensitisation in cancer cells by berberine and coralyne
MX2025009228A (es) Molecula de union a antigeno triespecifica y uso de la misma
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
Navaeipour et al. Effects of continuous wave and fractionated diode laser on human fibroblast cancer and dermal normal cells by zinc phthalocyanine in photodynamic therapy: A comparative study
Mapp et al. Oxidative cleavage of DNA by pentamethine carbocyanine dyes irradiated with long-wavelength visible light
Serhatli et al. Morpholinoethoxy-substituted cationic metal-free and metallo phthalocyanines: in vitro photodynamic therapy activities, PDT-induced ROS level measurements, and cellular death mechanism
Berg et al. Mitotic inhibition by phenylporphines and tetrasulfonated aluminium phthalocyanine in combination with light
BR112022006739A2 (pt) Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
Urrutia et al. New azine compounds as photoantimicrobial agents against Staphylococcus aureus
Wang et al. Indocyanine green as effective antibody conjugate for intracellular molecular targeted photodynamic therapy

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]